Adam R. Craig - 16 Oct 2026 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Executive Chairman, Director
Issuer ticker: XFOR
Reported as of: 16 Oct 2026
Net transaction value: +$11,884
SEC form: 4
Accepted by SEC: 19 Oct 2026, 16:06:26 UTC
Prior SEC filing: 13 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ David Kirske, Attorney-In-Fact

Filing notes and source

Key filing fact

Adam R. Craig filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 19 Oct 2026.

Key facts

This page summarizes Adam R. Craig's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Oct 2026, 16:06.

Change

Previous filing in this sequence was filed on 13 Aug 2026.
Current net transaction value: +$11,884.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001339498 Primary reporting owner

Craig Adam R

Relationship: Executive Chairman, Director
Address: C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON
Signature: /s/ David Kirske, Attorney-In-Fact
Signature date: 19 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Purchase

Transaction value: $11,884
Shares: +4,600
Change %: +1.4%
Price: $2.58
Shares after: 333,251
Date: 16 Oct 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Of the shares of common stock reported, 193,254 shares represent restricted stock units.

Footnote F2

The Reporting Person has agreed to disgorge to the Issuer all profits deemed to be realized from this transaction pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended.